CY1123242T1 - Λυοφιλοποιημενο παρασκευασμα κυτταροτοξικων διπεπτιδιων - Google Patents
Λυοφιλοποιημενο παρασκευασμα κυτταροτοξικων διπεπτιδιωνInfo
- Publication number
- CY1123242T1 CY1123242T1 CY20201100749T CY201100749T CY1123242T1 CY 1123242 T1 CY1123242 T1 CY 1123242T1 CY 20201100749 T CY20201100749 T CY 20201100749T CY 201100749 T CY201100749 T CY 201100749T CY 1123242 T1 CY1123242 T1 CY 1123242T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cyclodextrin
- preparation
- lyofrized
- cytotoxic dipeptides
- dipeptides
- Prior art date
Links
- 108010016626 Dipeptides Proteins 0.000 title abstract 2
- 231100000433 cytotoxic Toxicity 0.000 title abstract 2
- 230000001472 cytotoxic effect Effects 0.000 title abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000001116 FEMA 4028 Substances 0.000 abstract 2
- 229960004853 betadex Drugs 0.000 abstract 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- -1 Kremophor EL Chemical compound 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 abstract 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- YQZNKYXGZSVEHI-VXKWHMMOSA-N ethyl (2s)-2-[[(2s)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate Chemical compound C([C@@H](C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(=CC=1)N(CCCl)CCCl)C1=CC=C(F)C=C1 YQZNKYXGZSVEHI-VXKWHMMOSA-N 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 229950009924 melphalan flufenamide Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 229950008882 polysorbate Drugs 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- 125000004862 thiobutyl group Chemical group 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
- 150000003852 triazoles Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A61K38/105—Bombesin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Η παρούσα εφεύρεση κατευθύνεται στις νέες λυοφιλοποιημένες φαρμακευτικές συνθέσεις που περιέχουν κυτταροτοξικά διπεπτίδια όπως είναι η μελφαλάνη φλουφεναμίδη και ένα ή περισσότερα έκδοχα που επιλέγονται από την ομάδα που αποτελείται από ένα πολυσορβικό άλας, μια πολυαίθυλενο γλυκόλη, β- κυκλοδεξτρίνη, α-κυκλοδεξτρίνη, υδροξυπροπυλο- β-κυκλοδεξτρίνη, θειοβουτυλοαιθέρας- β- κυκλοδεξτρίνη, λακτόζη, βενζυλική αλκοόλη, ηλεκτρικό δινάτριο, προπυλενογλυκόλη, Κρεμοφόρο EL, διμέθυλο σουλφοξείδιο, D- μαννιτόλη, τρεαζόλη, σακχαρόζη και ένα αμινοξύ. Αυτό το παρασκεύασμα μπορεί να συντεθεί περαιτέρω και είναι χρήσιμο στη θεραπεία του καρκίνου.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1150371 | 2011-04-28 | ||
| US201161535126P | 2011-09-15 | 2011-09-15 | |
| EP12718949.6A EP2701720B1 (en) | 2011-04-28 | 2012-04-25 | Lyophilized preparation of cytotoxic dipeptides |
| PCT/EP2012/057577 WO2012146625A1 (en) | 2011-04-28 | 2012-04-25 | Lyophilized preparation of cytotoxic dipeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123242T1 true CY1123242T1 (el) | 2021-10-29 |
Family
ID=47071620
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101070T CY1119453T1 (el) | 2011-04-28 | 2017-10-12 | Λυοφιλοποιημενη παρασκευη κυτταροτοξικων διπεπτιδιων |
| CY20201100749T CY1123242T1 (el) | 2011-04-28 | 2020-08-12 | Λυοφιλοποιημενο παρασκευασμα κυτταροτοξικων διπεπτιδιων |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101070T CY1119453T1 (el) | 2011-04-28 | 2017-10-12 | Λυοφιλοποιημενη παρασκευη κυτταροτοξικων διπεπτιδιων |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US20140128462A1 (el) |
| EP (4) | EP2701720B1 (el) |
| JP (1) | JP6042412B2 (el) |
| KR (2) | KR102122416B1 (el) |
| CN (2) | CN108096563A (el) |
| AU (1) | AU2012247545B2 (el) |
| BR (2) | BR122019017088B1 (el) |
| CA (2) | CA3024230C (el) |
| CY (2) | CY1119453T1 (el) |
| DK (3) | DK3228319T3 (el) |
| ES (2) | ES2930140T3 (el) |
| FI (1) | FIC20230004I1 (el) |
| FR (1) | FR23C1000I2 (el) |
| HR (2) | HRP20221355T1 (el) |
| HU (3) | HUE037863T2 (el) |
| IL (3) | IL228889A0 (el) |
| LT (2) | LT2701720T (el) |
| MX (1) | MX345102B (el) |
| NL (1) | NL301206I2 (el) |
| NO (1) | NO2023004I1 (el) |
| PL (3) | PL3228319T3 (el) |
| PT (2) | PT2701720T (el) |
| RS (3) | RS63747B1 (el) |
| RU (1) | RU2597154C2 (el) |
| SI (2) | SI3228319T1 (el) |
| WO (1) | WO2012146625A1 (el) |
| ZA (1) | ZA201308765B (el) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2701720B1 (en) | 2011-04-28 | 2017-07-12 | Oncopeptides AB | Lyophilized preparation of cytotoxic dipeptides |
| JP5827178B2 (ja) * | 2012-06-05 | 2015-12-02 | 北越紀州製紙株式会社 | セルロース多孔質体及びその製造方法 |
| JP6284945B2 (ja) * | 2012-10-26 | 2018-02-28 | オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ | メルファランフルフェナミドの凍結乾燥製剤 |
| LT2928463T (lt) * | 2012-10-26 | 2020-02-10 | Oncopeptides Ab | Liofilizuoti melfalano flufenamido preparatai |
| GB201507903D0 (en) | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
| US10369077B2 (en) * | 2017-05-31 | 2019-08-06 | Adienne Pharma & Biotech Sa | Multi chamber flexible bag and methods of using the same |
| ES2942468T3 (es) * | 2018-10-18 | 2023-06-01 | Oncopeptides Ab | Compuestos que contienen deuterio |
| EP3946309A1 (en) | 2019-04-03 | 2022-02-09 | Oncopeptides AB | Treatment of al amyloidosis with melflufen |
| GB201905477D0 (en) * | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
| WO2021053185A1 (en) | 2019-09-20 | 2021-03-25 | Oncopeptides Ab | Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma |
| CA3176803A1 (en) * | 2020-05-08 | 2021-11-11 | Cjb Applied Technologies, Llc | Pesticidal compositions and related methods |
| EP4366721A1 (en) | 2021-07-08 | 2024-05-15 | Oncopeptides Innovation AB | Melflufen for use in the treatment of multiple myeloma |
| GB202109894D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109895D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109896D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202204171D0 (en) | 2022-03-24 | 2022-05-11 | Oncopeptides Ab | Novel formulations |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB750155A (en) | 1953-03-17 | 1956-06-13 | Nat Res Dev | Substituted alanines |
| GB8727157D0 (en) * | 1987-11-19 | 1987-12-23 | Wellcome Found | Pharmaceutical formulations |
| JP3176716B2 (ja) | 1991-06-21 | 2001-06-18 | 武田薬品工業株式会社 | 溶解性が向上した難水溶性薬物組成物 |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| DE60141398D1 (de) | 2000-06-13 | 2010-04-08 | Oncopeptides Ab | Melphalan-derivate und ihre verwendung als chemotherapeutika gegen krebs |
| SE0002202D0 (sv) * | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| WO2003035030A1 (en) | 2001-10-24 | 2003-05-01 | Pari Gmbh | Kit for the preparation of a pharmaceutical composition |
| AR038535A1 (es) * | 2002-02-22 | 2005-01-19 | Schering Corp | Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos |
| US6780324B2 (en) * | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US20040034099A1 (en) * | 2002-06-27 | 2004-02-19 | Ramsey Beverly J. | Pharmaceutical composition |
| US20050152979A1 (en) * | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
| JP4971160B2 (ja) | 2004-08-12 | 2012-07-11 | シェーリング コーポレイション | 安定するｐｅｇ化インターフェロン処方物 |
| RU2382647C2 (ru) * | 2004-10-29 | 2010-02-27 | Фарма Мар С.А., Сосьедад Униперсональ | Композиции, содержащие эктинэсайдин и дисахарид |
| EP1674098A1 (en) | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| US7754720B2 (en) | 2006-07-07 | 2010-07-13 | Gilead Sciences, Inc. | Pyridazine compound and use thereof |
| PT2101731T (pt) | 2006-11-21 | 2018-04-18 | Jina Pharmaceuticals Inc | Endoxifeno para utilização no tratamento de cancro |
| CN101584669B (zh) * | 2009-06-19 | 2010-12-29 | 江苏奥赛康药业有限公司 | 美法仑冻干粉针剂 |
| WO2011078782A1 (en) * | 2009-12-22 | 2011-06-30 | Oncopeptides Ab | A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer |
| AR077384A1 (es) | 2010-07-05 | 2011-08-24 | Eriochem Sa | Una formulacion farmaceutica inyectable de melfalano. |
| AU2012241726C1 (en) * | 2011-04-15 | 2017-09-14 | Janssen Pharmaceutica Nv | Freeze dried drug nanosuspensions |
| EP2701720B1 (en) | 2011-04-28 | 2017-07-12 | Oncopeptides AB | Lyophilized preparation of cytotoxic dipeptides |
| JP6284945B2 (ja) | 2012-10-26 | 2018-02-28 | オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ | メルファランフルフェナミドの凍結乾燥製剤 |
-
2012
- 2012-04-25 EP EP12718949.6A patent/EP2701720B1/en active Active
- 2012-04-25 PL PL17173249T patent/PL3228319T3/pl unknown
- 2012-04-25 PL PL12718949T patent/PL2701720T3/pl unknown
- 2012-04-25 CN CN201810054866.9A patent/CN108096563A/zh active Pending
- 2012-04-25 ES ES19215699T patent/ES2930140T3/es active Active
- 2012-04-25 DK DK17173249.8T patent/DK3228319T3/da active
- 2012-04-25 EP EP17173249.8A patent/EP3228319B1/en active Active
- 2012-04-25 RU RU2013152751/15A patent/RU2597154C2/ru active
- 2012-04-25 DK DK19215699.0T patent/DK3656393T3/da active
- 2012-04-25 MX MX2013012545A patent/MX345102B/es active IP Right Grant
- 2012-04-25 LT LTEP12718949.6T patent/LT2701720T/lt unknown
- 2012-04-25 SI SI201231829T patent/SI3228319T1/sl unknown
- 2012-04-25 PL PL19215699.0T patent/PL3656393T3/pl unknown
- 2012-04-25 PT PT127189496T patent/PT2701720T/pt unknown
- 2012-04-25 EP EP19215699.0A patent/EP3656393B1/en active Active
- 2012-04-25 BR BR122019017088-6A patent/BR122019017088B1/pt active IP Right Grant
- 2012-04-25 RS RS20221059A patent/RS63747B1/sr unknown
- 2012-04-25 SI SI201231086T patent/SI2701720T1/sl unknown
- 2012-04-25 KR KR1020177035122A patent/KR102122416B1/ko active IP Right Grant
- 2012-04-25 HR HRP20221355TT patent/HRP20221355T1/hr unknown
- 2012-04-25 WO PCT/EP2012/057577 patent/WO2012146625A1/en active Application Filing
- 2012-04-25 RS RS20201030A patent/RS60719B1/sr unknown
- 2012-04-25 RS RS20171002A patent/RS56462B1/sr unknown
- 2012-04-25 EP EP22191185.2A patent/EP4122482A1/en active Pending
- 2012-04-25 AU AU2012247545A patent/AU2012247545B2/en active Active
- 2012-04-25 PT PT192156990T patent/PT3656393T/pt unknown
- 2012-04-25 KR KR1020137031096A patent/KR101808895B1/ko active IP Right Grant
- 2012-04-25 HU HUE12718949A patent/HUE037863T2/hu unknown
- 2012-04-25 JP JP2014506850A patent/JP6042412B2/ja active Active
- 2012-04-25 ES ES12718949.6T patent/ES2642676T3/es active Active
- 2012-04-25 LT LTEP19215699.0T patent/LT3656393T/lt unknown
- 2012-04-25 DK DK12718949.6T patent/DK2701720T3/en active
- 2012-04-25 HU HUE19215699A patent/HUE060783T2/hu unknown
- 2012-04-25 BR BR112013027584-7A patent/BR112013027584B1/pt active IP Right Grant
- 2012-04-25 CA CA3024230A patent/CA3024230C/en active Active
- 2012-04-25 US US14/113,768 patent/US20140128462A1/en not_active Abandoned
- 2012-04-25 CN CN201280019920.7A patent/CN103547279A/zh active Pending
- 2012-04-25 CA CA2833500A patent/CA2833500C/en active Active
-
2013
- 2013-10-15 IL IL228889A patent/IL228889A0/en active IP Right Grant
- 2013-11-21 ZA ZA2013/08765A patent/ZA201308765B/en unknown
-
2016
- 2016-08-01 US US15/225,323 patent/US10322182B2/en active Active
-
2017
- 2017-10-10 HR HRP20171523TT patent/HRP20171523T1/hr unknown
- 2017-10-12 CY CY20171101070T patent/CY1119453T1/el unknown
-
2019
- 2019-03-19 IL IL265457A patent/IL265457B/en active IP Right Grant
- 2019-04-12 US US16/382,276 patent/US10543274B2/en active Active
- 2019-06-28 US US16/457,102 patent/US20200009252A1/en not_active Abandoned
- 2019-12-19 US US16/721,639 patent/US10869928B2/en active Active
-
2020
- 2020-02-03 IL IL272429A patent/IL272429B/en unknown
- 2020-07-22 US US16/935,372 patent/US11344622B2/en active Active
- 2020-08-12 CY CY20201100749T patent/CY1123242T1/el unknown
-
2022
- 2022-04-27 US US17/730,398 patent/US11896668B2/en active Active
- 2022-12-13 NL NL301206C patent/NL301206I2/nl unknown
-
2023
- 2023-01-04 FR FR23C1000C patent/FR23C1000I2/fr active Active
- 2023-01-16 HU HUS2300005C patent/HUS2300005I1/hu unknown
- 2023-01-16 NO NO2023004C patent/NO2023004I1/no unknown
- 2023-01-19 FI FIC20230004C patent/FIC20230004I1/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123242T1 (el) | Λυοφιλοποιημενο παρασκευασμα κυτταροτοξικων διπεπτιδιων | |
| CY1120137T1 (el) | Ενεσιμα σκευασματα βοτουλινικης τοξινης | |
| CY1119177T1 (el) | Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων | |
| CY1119256T1 (el) | Βελτιωμενες συνθεσεις και μεθοδοι για λυοφιλοποιηση και προϊοντα λυοφιλοποιησης που παρεχονται απο αυτες | |
| CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
| CY1121411T1 (el) | Σταθερες φαρμακοτεχνικες μορφες πολυπεπτιδιων και χρησεις αυτων | |
| AR127861A2 (es) | Composición farmacéutica que comprende inhibidores del proteasoma peptídico y ciclodextrina | |
| CY1121125T1 (el) | Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης | |
| CY1120670T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi) | |
| CY1116150T1 (el) | Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842 | |
| CY1114590T1 (el) | Εμβολια πεπτιδιου για καρκινους που εκφραζουν ογκο-συναφη αντιγονα | |
| CY1106824T1 (el) | Σταθερες ενεσιμες συνθεσεις δικλοφενακ | |
| SG10201811124YA (en) | Her2 antibody-drug conjugates | |
| JP2019518733A5 (el) | ||
| CY1119007T1 (el) | Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης | |
| CY1121466T1 (el) | Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης | |
| JP2014512402A5 (el) | ||
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| NZ613252A (en) | Peptide epoxyketones for proteasome inhibition | |
| WO2012116272A3 (en) | Polymer conjugated protein micelles | |
| EA201001143A1 (ru) | Активаторы прокаспаз "исполнителей" 3, 6 и 7 | |
| MX2012001953A (es) | Composiciones fotosensibilizantes. | |
| RU2020111026A (ru) | Препараты даптомицина | |
| CY1120724T1 (el) | Ενεση 5 αλφα-ανδροστανο (αλκυλο)-3-βητα,5,6 βητα-τριολης και μεθοδος παρασκευης για αυτη | |
| CY1120793T1 (el) | Μεθοδοι θεραπευτικης αγωγης παθησεων που αφορουν μαλλια |